Subscribe to the Daily PV Brief for breaking drug safety news, regulatory updates, and pharmacovigilance insights.
Daily News and Intelligence for the Pharmacovigilance Industry
Stay informed with timely coverage of drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, compliance trends, and career insights from across the global PV landscape.
FDA Warns 30 Telehealth Firms Over Compounded GLP-1 Claims
FDA has issued 30 warning letters to telehealth companies over false or misleading claims tied to compounded GLP-1 products.
Today in PV
A quick scan of the latest stories, safety concerns, regulatory developments, and industry signals every pharmacovigilance professional should know today.
Explore Coverage
Browse the key areas shaping pharmacovigilance today, from global regulatory updates to safety signals, compliance trends, AI, and career growth.
Regulatory Updates
Track key developments from FDA, EMA, MHRA, WHO, NAFDAC, Health Canada, TGA, SAHPRA, and other health authorities.
Inspections & Compliance
Stay current on inspection readiness, CAPAs, SOP expectations, audit trends, and the compliance issues shaping PV systems.
Explainers
Clear, practical breakdowns of PV concepts, industry terms, reporting frameworks, and regulatory changes.
Careers
Insights for professionals building or advancing careers in pharmacovigilance, drug safety, compliance, and related functions.
Safety Signals
Follow emerging risks, label changes, recalls, medication errors, and other safety issues that matter in real-world pharmacovigilance.
AI & Digital PV
Explore how artificial intelligence, automation, and digital tools are influencing case processing, signal detection, and safety operations.
Latest News
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam. Aque ipsa quae ab illo inventore veritatis. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accus antium doloremque.
Why MHRA’s 30-Day Type II Safety Variation Route Matters
MHRA’s reduced 30-day Type II route for safety issues shows that some pharmacovigilance-driven changes require a faster regulatory response than standard variation timelines.
What MHRA’s February 2026 Safety Roundup Signals for Drug Safety Teams
MHRA’s February 2026 Safety Roundup is a useful reminder that regulators are increasingly packaging practical safety advice in faster, easier-to-scan formats.
MHRA Highlights Very Rare NAION Risk with Semaglutide
MHRA has updated semaglutide safety information to reflect the very rare risk of NAION, adding a new vision-related warning for prescribers and patients to watch closely.
MHRA’s National Assessment Procedure Update: Why It Matters in 2026
MHRA updated its national assessment procedure guidance in February 2026, another reminder that UK regulatory pathways are continuing to evolve post-Brexit and post-Windsor.
Why MHRA’s 30-Day Type II Safety Variation Route Matters
MHRA’s reduced 30-day Type II procedure for safety issues is a useful signal that some pharmacovigilance-driven changes need faster regulatory handling than standard variation timelines allow.
What MHRA’s February 2026 Safety Roundup Signals for Drug Safety Teams
MHRA’s February 2026 Safety Roundup is a useful reminder that regulators are increasingly packaging practical safety advice in ways teams can scan and act on quickly.
Featured Posts
FDA Adds Earlier MRI Monitoring for Leqembi Patients
FDA is requiring earlier MRI monitoring for patients taking Leqembi, a move that shows how postmarketing safety findings can quickly reshape real-world risk management.
Industry Alert: Rising Scrutiny Over Proxy Interviews, False Representation, and Intermediary Misconduct in Pharmacovigilance Hiring
A growing wave of scrutiny is falling not only on candidates accused of false representation, but also on the broader network of intermediaries, facilitators, and operators involved in questionable pharmacovigilance hiring routes.
Why XEVMPD Knowledge Still Matters for Modern PV Professionals
Product-data competence may not sound glamorous, but EMA’s 2026 XEVMPD training schedule shows it still matters for pharmacovigilance in practice.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Contact us
Email Us
editor@pvwatchdaily.com